5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine: A Keystone for Selective α2-AR Signaling Research

Introduction: The Need for Precision in α2-Adrenergic Receptor Agonist Research

In the rapidly evolving landscape of receptor signaling and immune modulation, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (SKU B3465) is emerging as a cornerstone for scientists demanding rigor and reproducibility. As a highly pure, DMSO-soluble, small molecule α2-adrenergic receptor (α2-AR) agonist, this compound—sourced from APExBIO—is engineered for high-fidelity studies across neuroscience, immunology, and translational oncology. Its particular relevance is underscored in recent studies leveraging α2-AR activation to modulate immune rejection in post-surgery osteosarcoma recurrence treatment. Here, we dissect its experimental advantages, optimized workflows, and troubleshooting strategies, while mapping out its future translational impact.

Principle and Product Overview

5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a selective α2-adrenergic receptor agonist with a molecular weight of 292.13 and chemical formula C₁₁H₁₀BrN₅. It is structurally designed to activate α2-ARs, a subclass of G protein-coupled receptors (GPCRs) pivotal in modulating neurotransmitter release, vascular tone, and immune responses. Notably, this compound is insoluble in water or ethanol but demonstrates robust solubility in DMSO (≥25.7 mg/mL with ultrasonic assistance), ensuring compatibility with advanced cell-based and in vivo models.

Key quality attributes include:

• High Purity: 98–99.88% (HPLC/NMR verified)
• DMSO Solubility: ≥25.7 mg/mL, enabling high-concentration stock solutions
• Stability: Best used immediately after DMSO dissolution; store at –20°C
• Intended Use: For research, not clinical or diagnostic applications

As a small molecule receptor agonist, its utility extends from fundamental receptor biology to applied models of immune rejection modulation, notably in post-surgery osteosarcoma recurrence research.

Step-by-Step Experimental Workflow and Protocol Enhancements

1. Reagent Preparation and Handling

• Upon receipt (shipped on blue ice), store immediately at –20°C in a desiccated environment.
• For experimental use, dissolve the desired amount in 100% DMSO to achieve a stock concentration up to 25.7 mg/mL. Sonicate if necessary to ensure full dissolution.
• Prepare aliquots to minimize freeze-thaw cycles; use freshly thawed solutions for each experiment to preserve compound integrity and activity.

2. In Vitro Applications: Immune and Osteosarcoma Models

• Cell Viability and Migration: Employ concentrations informed by literature (e.g., 1–10 μM) in CCK-8, scratch wound healing, and Transwell assays using osteosarcoma lines (K7M2, 143b, Khos). Notably, no significant cytotoxicity was observed at these concentrations, confirming specificity for receptor signaling over direct toxicity (reference study).
• Receptor Signaling Assays: For T cell activation and α2-AR pathway interrogation, apply validated concentrations in primary immune cell cultures or Jurkat T cells, measuring downstream readouts such as CD8⁺ T cell activation, TCR pathway phosphorylation, and cytokine secretion.

3. In Vivo Applications: Post-surgery Osteosarcoma Recurrence Models

• Utilize mouse models (e.g., BALB/c nude and immunocompetent BALB/c) with subcutaneous xenografts. After surgical resection, administer the compound via a thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained, localized delivery.
• Monitor tumor recurrence and growth via caliper measurements and imaging, comparing treated vs. control cohorts.
• Perform proteomic and bioinformatics analysis (Metascape, STRING, Cytoscape, TCGA/GTEx) to quantify TME changes and T cell activation (ITGAL, MSN, TOLLIP as markers).

For detailed product specifics and ordering, visit the 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine product page at APExBIO.

Advanced Applications and Comparative Advantages

What distinguishes this selective α2-AR agonist for receptor signaling research is its capacity to elucidate immune rejection mechanisms in both in vitro and in vivo contexts, particularly in the challenging scenario of osteosarcoma recurrence. Key findings from the reference study demonstrate:

• Immune Modulation without Direct Cytotoxicity: In vitro, the compound did not significantly impact OS cell viability or migration, underscoring a mechanism based on immune signaling rather than tumor cell toxicity (see reference).
• Enhanced Anti-tumor Immunity In Vivo: When delivered via hydrogel, treated animals exhibited a statistically significant reduction in tumor recurrence (data: recurrence rates dropped by >50% compared to controls), correlating with upregulated CD8⁺ T cell activity and TCR signaling.
• Mechanistic Insights via Proteomics: Analysis of the tumor microenvironment (TME) revealed modulation of immune pathways, with ITGAL as a central regulatory node, supporting the role of α2-AR signaling in orchestrating a robust anti-tumor response.

This approach complements and extends previous findings. For instance, the article "5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a high-purity, DMSO-soluble, small molecule α2-adrenergic receptor agonist" specifically highlights the compound’s reproducibility in T cell activation assays, while "Enhancing α2-AR Signaling Research" addresses common challenges in α2-AR studies and demonstrates how APExBIO’s formulation ensures sensitivity and reliability. Together, these resources establish the compound’s leadership in immune modulation and mechanistic studies, and the present workflow integrates their best practices for maximal experimental fidelity.

Troubleshooting and Optimization Tips

• Solubility Issues: If undissolved particulates are observed, confirm that DMSO is anhydrous and apply additional sonication. Avoid water/ethanol as solvents due to complete insolubility.
• Solution Stability: Prepare fresh working aliquots immediately before use; prolonged storage (even at –20°C) can reduce activity due to hydrolysis or oxidation.
• Batch Variability: Always verify lot-specific purity via HPLC or NMR provided by APExBIO; purity ranges of 98–99.88% ensure consistency across experiments.
• In Vivo Delivery: Employ slow-release hydrogels (PLGA-PEG-PLGA) for sustained local dosing—rapid systemic clearance can otherwise limit efficacy and confound immune readouts.
• Negative/Off-target Effects: Use appropriate negative controls (vehicle-only, unrelated agonists) to confirm specificity for α2-AR signaling. Monitor for unexpected behavioral or physiological responses in animal studies.
• Assay Sensitivity: For T cell or TCR pathway studies, titrate concentrations based on cell type and endpoint; higher concentrations may induce non-specific effects in sensitive primary cultures.

These points are reinforced by the troubleshooting section in "5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a well-characterized, small molecule selective α2-adrenergic receptor agonist", which details optimal handling and control strategies.

Future Outlook: Expanding the Impact of α2-AR Agonists in Translational Science

The translational potential of 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine extends far beyond osteosarcoma. As highlighted in "Unlocking the Translational Potential of Selective α2-Adrenergic Receptor Agonists", its application in immune rejection modulation and next-generation receptor signaling research positions it as a pivotal tool for both mechanistic and clinical pipeline development. Immediate frontiers include:

• Combinatorial Immunotherapy: Pairing α2-AR agonists with immune checkpoint inhibitors or targeted therapies for synergistic anti-tumor effects.
• Advanced Biomaterial Delivery: Integrating the compound into nano- or micro-engineered matrices for precise tissue targeting and temporal control.
• Neuroscience Applications: Leveraging its role in neurotransmitter modulation to dissect brain-immune axis mechanisms in neuroinflammation and neurodegenerative models.
• Personalized Medicine: Using proteomic and genomic markers (e.g., ITGAL, MSN, TOLLIP) to stratify patients likely to benefit from α2-AR pathway modulation.

As research advances, the combination of robust DMSO solubility, high purity, and validated workflow protocols ensures that 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine from APExBIO remains at the forefront of selective α2-AR agonist research and immune modulation innovation.

Conclusion

With its high purity, reliable DMSO solubility, and proven effectiveness in both mechanistic and translational studies, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is a superior choice for scientists investigating G protein-coupled receptor agonist signaling, immune rejection modulation, and post-surgery osteosarcoma recurrence treatment research. By adhering to best practices in reagent handling, experimental design, and troubleshooting, and by leveraging the latest insights from foundational and applied research, investigators can unlock the full power of this selective α2-AR agonist for receptor signaling research and beyond.